BridgeMD
New treatment option for Lung Cancer
Official title Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer
ClinicalTrials.gov ID: NCT05849129
What this study is testing
What is Ascorbic acid?
Ascorbic acid is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for lung cancer.
Also referred to as Vitamin C.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 5 years
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults (≥18 years of age) seen at TOHCC with stage IIIB or IV primary non-small cell lung cancer
- Eligible and scheduled for first line platinum-doublet chemotherapy with or without concurrent immunotherapy
You likely can't join if
- ECOG status greater than 2
- Previously received IVC within 6 months prior to randomization
- Biochemical deficiency in G6PD
- Estimated Glomerular Filtration Rate (eGFR) less than 45 mL/min
- Currently taking insulin or warfarin
- History of severe renal dysfunction or hemochromatosis
See the full eligibility criteria
- Adults (≥18 years of age) seen at TOHCC with stage IIIB or IV primary non-small cell lung cancer
- Eligible and scheduled for first line platinum-doublet chemotherapy with or without concurrent immunotherapy
- ECOG status greater than 2
- Previously received IVC within 6 months prior to randomization
- Biochemical deficiency in G6PD
- Estimated Glomerular Filtration Rate (eGFR) less than 45 mL/min
- Currently taking insulin or warfarin
- History of severe renal dysfunction or hemochromatosis
- Previously undergone cytotoxic chemotherapy or immunotherapy within 12 months prior to randomization
- If pregnant or planning to become pregnant: not a carrier of the gene for G6PD deficiency
- Currently taking an investigational product or participation in an investigational study within the past 30 days
- Any reason which, under the discretion of the Principal Investigator or delegate, would preclude the patient from participating
The study team makes the final eligibility decision.
Where it's taking place
- Ottawa, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 5 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ottawa, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.